Trexquant Investment LP Takes Position in OptimizeRx Corp. $OPRX

Trexquant Investment LP bought a new position in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 54,262 shares of the company's stock, valued at approximately $470,000. Trexquant Investment LP owned approximately 0.29% of OptimizeRx at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Blair William & Co. IL raised its stake in OptimizeRx by 4.9% during the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company's stock valued at $5,465,000 after acquiring an additional 29,648 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of OptimizeRx by 298.8% in the fourth quarter. Squarepoint Ops LLC now owns 41,712 shares of the company's stock worth $203,000 after buying an additional 31,252 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in shares of OptimizeRx by 47.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 124,751 shares of the company's stock worth $1,080,000 after purchasing an additional 39,969 shares during the last quarter. Jane Street Group LLC increased its stake in OptimizeRx by 234.7% during the fourth quarter. Jane Street Group LLC now owns 72,454 shares of the company's stock valued at $352,000 after acquiring an additional 50,808 shares during the period. Finally, Calamos Advisors LLC bought a new stake in shares of OptimizeRx in the 1st quarter valued at approximately $289,000. Institutional investors and hedge funds own 76.47% of the company's stock.

Insiders Place Their Bets

In other news, Director Patrick D. Spangler sold 11,120 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $17.49, for a total transaction of $194,488.80. Following the completion of the sale, the director directly owned 44,215 shares in the company, valued at approximately $773,320.35. This represents a 20.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.60% of the stock is owned by corporate insiders.

OptimizeRx Stock Performance

OPRX stock traded down $1.50 during midday trading on Friday, reaching $17.33. 576,632 shares of the company's stock traded hands, compared to its average volume of 330,790. The company has a 50-day moving average price of $15.36 and a two-hundred day moving average price of $11.88. The firm has a market capitalization of $321.73 million, a PE ratio of -32.09 and a beta of 1.20. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.57 and a current ratio of 2.57. OptimizeRx Corp. has a 52 week low of $3.78 and a 52 week high of $19.25.

Analyst Upgrades and Downgrades

OPRX has been the topic of several research reports. Roth Capital reissued a "buy" rating on shares of OptimizeRx in a research note on Friday, August 8th. JMP Securities raised their price objective on OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a report on Monday, August 11th. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Stifel Nicolaus upped their price target on shares of OptimizeRx from $16.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Finally, Zacks Research upgraded OptimizeRx from a "hold" rating to a "strong-buy" rating in a report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, OptimizeRx currently has a consensus rating of "Moderate Buy" and an average price target of $11.81.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.